SciELO - Scientific Electronic Library Online

vol.146 issue2Pattern of smoking and socioeconomic status in two cohorts of young adultsOutcome of surgery for Crohn's colitis. Review of 28 cases author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Revista médica de Chile

Print version ISSN 0034-9887


LEON, Pilar et al. Acquired aplastic anemia. Experience in a public hospital. Rev. méd. Chile [online]. 2018, vol.146, n.2, pp.175-182. ISSN 0034-9887.


The first line treatment for patients < 40 years old with aplastic anemia (AA) is allogeneic HLA-identical sibling donor transplantation (SCT). Immunosuppressive therapy (IST) with a combination of Thymoglobuline (ATG) and cyclosporine is used for older patients or those without a donor. Five year overall survival (OS) for both therapies is > 70%.


To report the experience with SCT and ATG for AA in a public hospital.

Patients and Methods:

AA was diagnosed in 42 patients between 1998 and 2016, according to Camitta criteria. Thirty eight (90%) received treatment, 7 (18%) under 40 years old received SCT, and 31 (82%) IST. The rest were not treated. OS was calculated from date of diagnosis until last control, death or loss from follow up.


Complete or partial hematologic response, was obtained in 71% and 58% of cases with SCT and IS, respectively. Five year OS was 71% and 55% with SCT and IST, respectively. No difference in response was observed between horse and rabbit ATG.


SCT from an HLA-identical sibling donor had a high response rate and survival. IST instead, had a lower response and survival, due to an initial high mortality rate.

Keywords : Anemia; Aplastic; Homologous; Immunosuppression; Stem Cell Transplantation; Transplantation.

        · text in Spanish     · Spanish ( pdf )